Motley Fool Next Index ETF
TMFX - ETF AI Analysis
Top Page
Motley Fool Next Index ETF (TMFX)
TMFX’s rating suggests it is a solid but not top-tier ETF, supported by several strong companies with good financial performance and growth prospects. Holdings like HEICO, EQT, Biogen, Okta, Illumina, and Cboe Global Markets contribute positively through strong earnings, bullish or stable momentum, and strategic initiatives in areas like AI and operational efficiency. However, weaker names such as Crown Castle and Rocket Companies, which face financial and valuation challenges, slightly drag on the fund’s quality, and investors should note the risk that some holdings show bearish technical signals or overvaluation despite their growth stories.
TMFX vs. SPDR S&P 500 ETF (SPY)
- AUM
- 38.63M
- Region
- North America
- Expense Ratio
- 0.50%
- Beta
- 1.03
- Issuer
- Motley Fool
- Inception Date
- Dec 29, 2021
- Dividend Yield
- 0.04%
- Asset Class
- Equity
- Index Tracked
- Motley Fool Next Index - Benchmark TR Gross
TMFX Summary
TMFX is the Motley Fool Next Index ETF, which follows the Motley Fool Next Index and focuses on smaller and mid-sized U.S. companies outside the big blue-chip names. It spreads investments across areas like technology, health care, and industrials, aiming to find tomorrow’s potential leaders. Well-known holdings include Illumina in biotech and Roblox in online gaming. Someone might invest in TMFX for growth potential and diversification beyond large, established companies. A key risk is that smaller and mid-sized stocks can be more volatile, so the ETF’s value can go up and down more sharply with the market.
How much will it cost me?
TMFX has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. This is higher than the average low-cost index ETF because it follows a more specialized, research-driven strategy rather than a plain, broad market index.
What would affect this ETF?
This ETF is heavily focused on U.S. mid- and small-cap companies in technology, health care, and industrials, so it could benefit if the economy grows steadily, innovation continues, and interest rates eventually ease, making growth stocks more attractive. On the downside, higher-for-longer interest rates, economic slowdowns that hit smaller companies harder, or tighter regulations on areas like biotech, cybersecurity, and online gaming could weigh on top holdings such as Illumina, Zscaler, Roblox, and Biogen.
TMFX Top 10 Holdings
TMFX leans heavily into U.S. mid- and small-cap innovators, with a clear tilt toward tech and health care. Rising names like Zscaler and Okta are helping power returns, riding strong demand for cybersecurity and cloud-based tools. Illumina and Biogen add a steady, science-driven backbone from the health care side, supporting the fund when markets get choppy. On the weaker end, Roblox has been more mixed and is holding the fund back a bit, while Old Dominion Freight’s softer stretch shows the portfolio isn’t all high-growth glamour. Overall, it’s a U.S.-centric bet on tomorrow’s disruptors.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 RKT | Rocket Companies | 1.67% | $645.48K | $41.01B | -23.54% | 54Neutral |
 CCI | Crown Castle | 1.55% | $597.84K | $38.02B | -4.25% | 45Neutral |
 HEI | HEICO | 1.66% | $640.49K | $40.75B | 4.15% | 77Outperform |
 GEHC | GE Healthcare Technologies Inc | 1.57% | $605.54K | $37.82B | 9.15% | 78Outperform |
 CBOE | Cboe Global Markets | 1.60% | $619.08K | $38.06B | 41.40% | 75Outperform |
 BIIB | Biogen | 1.56% | $603.24K | $37.44B | 55.12% | 74Outperform |
 RMD | Resmed | 1.39% | $536.81K | $32.93B | -5.52% | 76Outperform |
 ODFL | Old Dominion Freight | 1.40% | $540.18K | $34.62B | 23.63% | 71Outperform |
 RBLX | Roblox | 1.49% | $574.15K | $36.64B | -50.72% | 51Neutral |
 ZS | Zscaler | 1.32% | $510.69K | $31.78B | -39.06% | 60Neutral |
TMFX Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMFX, the sentiment is Positive. The current price of 24.44 is below the 20-day moving average (MA) of 24.56, above the 50-day MA of 24.17, and above the 200-day MA of 22.56, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 54.89 is Neutral, neither overbought nor oversold. The STOCH value of 66.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMFX.
TMFX Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TMFX | $24.44 | $27.00(10.47% Upside) | $38.63M | 0.50% | 69Neutral |
 POMG | $27.32 | $34.02(24.52% Upside) | $79.20M | 0.68% | 66Neutral |
 FSCS | $37.78 | $42.27(11.87% Upside) | $62.80M | 0.60% | 74Outperform |
 MYLD | $33.01 | $37.80(14.50% Upside) | $54.01M | 0.62% | 68Neutral |
 BCSM | $24.88 | $31.96(28.46% Upside) | $37.38M | 0.75% | 59Neutral |
 IVSS | $30.40 | $37.07(21.96% Upside) | $30.41M | 0.59% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TMFX | Motley Fool Next Index ETF | 24.44 | 3.61 | 17.32% | |
| POMG | PRIMECAP Odyssey Discovery ETF | 27.32 | 1.80 | 7.05% | |
| FSCS | First Trust Smid Capital Strength Etf | 37.78 | 2.96 | 8.49% | |
| MYLD | Cambria Micro and SmallCap Shareholder Yield ETF | 33.01 | 8.30 | 33.61% | |
| BCSM | Baron SMID Cap ETF | 24.88 | 0.58 | 2.37% | |
| IVSS | Applied Finance IVS US SMID ETF | 30.40 | 5.18 | 20.53% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.